ArticleExpert review of vaccines2017
A potent adjuvant effect of a CD1d-binding NKT cell ligand in human immune system mice.
Article in Expert review of vaccines, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- The Road toward a Trojan Horse Malaria Vaccine: Chemical Augmentation of Live Sporozoites without Affecting Their Viability.Molecular pharmaceutics · 2026Article
- NKT cells-a generalist in disease treatment and a new key to unlock immunotherapy.Immunotherapy · 2025Review
- T Cell Development and Responses in Human Immune System Mice.Annual review of immunology · 2025Review
- Global trends and frontiers in iNKT cells: a bibliometric and visualized analysis.Frontiers in immunology · 2025Article
- Can invariant Natural Killer T cells drive B cell fate? a look at the humoral response.Frontiers in immunology · 2025Review
- A Humanized Mouse Model Coupled with Computational Analysis Identifies Potent Glycolipid Agonist of Invariant NKT Cells.ACS chemical biology · 2024Article
- Sex-Specific Differences in Cytokine Induction by the Glycolipid Adjuvant 7DW8-5 in Mice.Biomolecules · 2022Article
- An In Vivo Screen to Identify Short Peptide Mimotopes with Enhanced Antitumor Immunogenicity.Cancer immunology research · 2022Article
- A humanized mouse model forFrontiers in immunology · 2022Article
- Type I Natural Killer T Cells as Key Regulators of the Immune Response to Infectious Diseases.Clinical microbiology reviews · 2021Review
- Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141Frontiers in immunology · 2020Article
- A molecular switch in mouse CD1d modulates natural killer T cell activation by α-galactosylsphingamides.The Journal of biological chemistry · 2019Article
- Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies.Cancer research · 2018Article
- Development of a novel mechanism-based glycolipid adjuvant for vaccination.F1000Research · 2018Review
- Humanized Mouse Models for the Study of Human Malaria Parasite Biology, Pathogenesis, and Immunity.Frontiers in immunology · 2018Review
- Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses.Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
objectivesA CD1d-binding invariant natural killer T (iNKT)-cell stimulatory glycolipid, namely 7DW8-5, is shown to enhance the efficacy of radiation-attenuated sporozoites (RAS)-based malaria vaccine in mice. In the current study, we aim to determine whether 7DW8-5 can display a potent adjuvant effect in human immune system (HIS) mice.
methodsHIS-A2/hCD1d mice, which possess both functional human iNKT cells and CD8+ T cells, were generated by the transduction of NSG mice with adeno-associated virus serotype 9 expressing genes that encode human CD1d molecules and HLA-A*0201, followed by the engraftment of human hematopoietic stem cells. The magnitudes of human iNKT-cell response against 7DW8-5 and HLA-A*0201-restricted human CD8+ T-cell response against a human malaria antigen in HIS-A2/hCD1d mice were determined by using human CD1d tetramer and human HLA-A*0201 tetramer, respectively.
resultsWe found that 7DW8-5 stimulates human iNKT cells in HIS-A2/hCD1d mice, as well as those derived from HIS-A2/hCD1d mice in vitro. We also found that 7DW8-5 significantly increases the level of a human malarial antigen-specific HLA-A*0201-restricted human CD8+ T-cell response in HIS-A2/hCD1d mice.
conclusionsOur study indicates that 7DW8-5 can display a potent adjuvant effect on RAS vaccine-induced anti-malarial immunity by augmenting malaria-specific human CD8+ T-cell response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.